CapsoVision Q2 revenue rises on CapsoCam Plus capsules sales
CV•Analyst coverage
The one available analyst rating on the shares is "buy".
The average consensus recommendation for the advanced medical equipment and technology peer group is "buy".
Wall Street's median 12-month price target for CapsoVision Inc is $10.00, about 45.8% above its August 12 closing price of $6.86.
Margins and expenses
Gross margin declined to 51% from 55% due to pricing pressure and higher tariffs.
Operating expenses increased, mainly from clinical trials, engineering services, public company costs, and stock-based compensation.
| Metric | Actual |
|---|---|
| Q2 Revenue | $3.64 million |
| Q2 Gross Profit | $1.87 million |
| Q2 Operating Income | -$7.58 million |
| Q2 Pretax Loss | $7.48 million |
Outlook and product pipeline
The company anticipates FDA clearance of AI Highlights by the end of , with a U.S. launch soon after.
